Ipamorelin
Selective GH secretagogue with minimal cortisol and prolactin side effects.
Key Benefits
stimulates GH without raising cortisol or prolactin
combines powerfully with CJC-1295 for amplified GH pulses
preclinical data shows improvements in bone mineral density
no appetite stimulation or cortisol spike unlike other GHRPs
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
Ipamorelin binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, stimulating GH release via a cAMP-independent pathway. Its selectivity for GH over ACTH/cortisol is due to its pentapeptide structure, which avoids off-target receptor activation seen with other GHRPs.
Research Highlights
- Shown to increase GH pulse amplitude by 10–20× without elevating cortisol or prolactin
- Demonstrated synergistic GH release when combined with CJC-1295 or Sermorelin
- Preclinical data shows improvements in bone mineral density and lean mass
- Excellent safety profile in multiple animal studies — no desensitization at standard doses
Human observational or open-label study data exists. Controlled trial data may be limited. Not a treatment recommendation.
For laboratory research only
All Research Systems →Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →Recommended Stacks
Ipamorelin is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
GH Pulse Amplifier
The gold-standard two-signal GH stack — CJC-1295 + Ipamorelin for maximum physiological GH output.
Lean Body Recomposition
Build lean muscle while burning fat simultaneously — the holy grail of body composition research.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 5mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Ipamorelin binds the ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus, stimulating GH release via a cAMP-independent pathway. Its selectivity for GH over ACTH/cortisol is due to its pentapeptide structure, which avoids off-target receptor activation seen with other GHRPs.
Clinical Context
Ipamorelin is frequently combined with GHRH analogs (CJC-1295, Sermorelin) to produce synergistic GH pulses. The combination mimics the natural two-signal GH release mechanism more closely than either peptide alone.
Research Highlights
- Shown to increase GH pulse amplitude by 10–20× without elevating cortisol or prolactin
- Demonstrated synergistic GH release when combined with CJC-1295 or Sermorelin
- Preclinical data shows improvements in bone mineral density and lean mass
- Excellent safety profile in multiple animal studies — no desensitization at standard doses
Storage & Reconstitution
Store at -20°C. Reconstitute with 2 mL bacteriostatic water → 2.5 mg/mL. Stable 30 days at 2–8°C.
Key Studies
Ipamorelin, the first selective growth hormone secretagogue
Raun K et al.
Ipamorelin stimulates GH release with high selectivity — unlike GHRP-2/6, it does not elevate cortisol or prolactin at any dose tested.
PubMed →Growth hormone-releasing properties of ipamorelin
Johansen PB et al.
Ipamorelin produced dose-dependent GH pulses with no desensitization at standard doses in multiple animal models.
PubMed →Effects of ipamorelin on body composition in rats
Svensson J et al.
Ipamorelin improved lean body mass and bone mineral density in rodent models without adverse metabolic effects.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Stimulates GH release from pituitary somatotrophs via cAMP-independent pathway
10–20× GH pulse amplitude without cortisol or prolactin elevation
Amplifies endogenous GHRH release for synergistic GH response
Side Effects & Adverse Events
- Mild injection site reactions
- Transient flushing
- Mild water retention
- Headache
- Dizziness
- None documented in research
Contraindications & Interactions
Synergistic Compounds
The classic GHRH + GHRP combination — produces 10× more GH than either peptide alone by activating both signals of the two-signal GH release mechanism.
Ipamorelin 200 mcg + CJC-1295 w/o DAC 100–200 mcg in same syringe, SubQ pre-sleep.
View Compound →Sermorelin (GHRH) + Ipamorelin (GHRP) dual-signal combination for synergistic pulsatile GH release.
Ipamorelin 200 mcg + Sermorelin 300 mcg in same syringe, SubQ pre-sleep.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States